BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — JP Morgan Healthcare Conference 2026
24 slides from BioStem Technologies's conference presentation, January 2026
Slide 1: JP Morgan Healthcare Conference January 2026
JP Morgan Healthcare Conference January 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies,
Slide 3: Corporate Profile
Corporate Profile • BioStem Technologies Inc. (OTC: BSEM) • Sector: Medtech (Placental tissue allografts) • Stage: Commercial stage; Revenue and adjusted EBITDA positive YTD thru Q3 2025 • Headquarters: Pompano Beach, FL • Share Price: $5.00 (As of January 9, 2026) • Market Capitalization: $84M • Ba
Slide 4: Our Company, Our Mission, Our Vision
Our Company We are a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived allografts for advanced wound care Our Mission To create and deliver the most advanced wound healing technologies in the world Our Vision To pioneer advanced
Slide 5: Corporate Highlights
Corporate Highlights Building a profitable and scalable MedTech company Company Snapshot Billion Dollar+ Market Data-driven Product • Founded in 2014 Opportunity* Portfolio • Commercial growth stage • >7M Medicare patients • Leading BioRetain® with chronic non-healing proprietary technology • Ticker
Slide 6: Billion Dollar+ Market Opportunity
Billion Dollar+ Market Opportunity 6
Slide 7: Targeting Access to Additional Sites of Care
Targeting Access to Additional Sites of Care Expanding to Hospital and Ambulatory Surgery Center sites doubles our market opportunity Sites of Care $600M US Placental $570M Tissue $500M Market Private HOPD Office $570M* $400M Mobile ASC $300M Opportunity Health to Double our Market $200M Access with
Slide 8: Chronic Non-healing Wounds Impact Millions of Patients Annually
Chronic Non-healing Wounds Impact Millions of Patients Annually PU, DFU and VLU represent 82% of all chronic wounds 7M+ Chronic Wound Patient Breakdown Surgical Wound/ Trauma PU DFU VLU Arterial 6% 12% Pressure Ulcers Diabetic Foot Ulcers Venous Leg Ulcers Underlying pathology: Underlying pathology:
Slide 9: Why We Win in 2026
Why We Win in 2026 Combining our legacy business with new sites of care will deliver volume growth and footprint expansion Surgical/Hospital Mobile/Office • Targeting penetration into hospital/surgical markets • New CMS pricing levels the playing field in 2026 Clinical and Cost Advantage • Market pr
Slide 10: Go-to-Market Strategy
Go-to-Market Strategy Multi-channel commercial execution model designed to drive volume growth in 2026+ Expanded Select National Direct Sales 2026 Distributors Team Commercial Go-to-Market Model New Regional Distributors / Portfolio ISAs Expansion and Clinical Data 10
Slide 11: Proven Proprietary Technology Powers (Expanded) Commercial Portfolio
Proven Proprietary Technology Powers (Expanded) Commercial Portfolio 11
Slide 12: Clinical Outcomes
Clinical Outcomes BioRetain® technology delivers proven clinical benefits RCT demonstrates significant increase BioRetain outperforms the competition in real world evidence in probability of wound closure Probability of W o u n d Closure Few er Applications Faster Closure Number of Applications Trea
Slide 13: BioRetain Optimizes Retention of Natural Tissue Properties
BioREtain® Optimizes Retention of Natural Tissue Properties Demonstrated superiority over competitors IL-1ra P D GF -BB H ya l u r o n a n Collagen 1a1 5.0E+07 4.84E+07 4.0E+04 38547.5908 1.83E+03 3.5E+04 33609.815 4.0E+07 3.0E+04 25197.6752 2.5E+04 3.0E+07 2.0E+04 2.0E+07 1.5E+04 480.31 1.0E+04 1.0
Slide 14: Financial Highlights
Financial Highlights 14
Slide 15: Revenue and Adjusted EBITDA
Revenue and Adjusted EBITDA Key Milestones Revenue* Adj EBITDA** Q2 2025 • Declined from Top 5 to 15th on the ASP list, impacting sales Q3 2025 • Lowered pricing to address our ASP list position – drove 41% growth in volume 41% growth • Restated financials; reduced $16.0 in volume $7.8 net Revenue w
Slide 16: Positioned for Success
Positioned for Success 16
Slide 17: Well-Positioned to Capitalize on Opportunities in the Chronic Wound and Adjacent Markets
Well-Positioned to Capitalize on Opportunities in the Chronic Wound and Adjacent Markets Drive Growth Diversify Portfolio Publish Data • Large, growing market with • Explore strategic acquisitions: • Utilize existing published DFU RCT significant adjacent • Technology assets in large data to win cus
Slide 18: Management Team
Management Team Accomplished team with deep industry experience Barry Hassett Morgan Kim SVP, Legal and Corporate Chief Commercial Officer Compliance Contact information: Jason Matuszewski, CEO – [email protected] Brandon Poe, CFO – [email protected] Noah Agron, VP, Corp Fin – nagron@biostemt
Slide 19: Thank you!
AN e = “AN Thank you! BioStem TECHNOLOGIES
Slide 20: Appendix
Appendix Positioned for Success 20
Slide 21: BioStem is Addressing a Billion Dollar+ Opportunity
BioStem is Addressing a Billion Dollar+ Opportunity Significant volume growth opportunity going into 2026 • *Chronic wound market size – 2-2.5% of the U.S. population. https://pubmed.ncbi.nlm.nih.gov/37756368/#:~:text=Chronic%20wounds%20impact%20the%20quality,population%20of%20the%20United%20States.
Slide 22: Processing Advanced Allografts
Processing Advanced Allografts BioREtain® is the underlying technology used in BioStem allografts Placental Donation Proprietary Technology Expectant mom Mom consents Delivery of Donated Microbiology Proprietary 4-Year shelf- introduced to to donate and healthy full-term placental tissue testing of
Slide 23: World-Class Manufacturing
World-Class Manufacturing AATB® accredited, cGTP facility State of the art, vertically integrated manufacturing facility Currently processing 30k sq cm monthly Capacity up to 100K sq cm monthly to support future growth 6,100 sq ft of dedicated manufacturing space 3,000 sq ft of ISO clean room space
Slide 24: Reconciliations to Adjusted EBITDA
Reconciliations to Adjusted EBITDA Note: Results are unaudited and as restated in Q3 2025 24
BioStem Technologies — JP Morgan Healthcare Conference 2026 on 6ix